Stew Kroll

Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II

R. Bellomo, L. Forni, K. Kashani, 2018, Critical care medicine.

Angiotensin II for the Treatment of Vasodilatory Shock

R. Bellomo, R. Wunderink, R. Favory, 2017, The New England journal of medicine.

Treatment With Angiotensin II Is Associated With Rapid Blood Pressure Response and Vasopressor Sparing in Patients With Vasoplegia After Cardiac Surgery: A Post-Hoc Analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) Study.

A. Khanna, S. Chatterjee, R. Panwar, 2020, Journal of cardiothoracic and vascular anesthesia.

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

J. Vose, A. Zelenetz, M. Kaminski, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial

R. Bellomo, A. Zarbock, A. Khanna, 2023, Critical Care.

Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS‐3) data

M. Abril, A. Khanna, Damian R Handisides, 2019, Journal of critical care.

Angiotensin II for the Treatment of Vasodilatory Shock

R. Bellomo, R. Wunderink, R. Favory, 2017, New England Journal of Medicine.

The authors reply.

R. Bellomo, L. Chawla, G. Tidmarsh, 2019, Critical Care Medicine.